HomeTop StoriesIndian-origin scientist finds cancer therapy safe for patients with HIV & TB

Indian-origin scientist finds cancer therapy safe for patients with HIV & TB

New Delhi, Oct 1 (IANS) In a significant breakthrough to help patients battling both HIV and tuberculosis (TB), a study led by an Indian-origin scientist found a cancer therapy that can help control TB and not interfere with combined antiretroviral therapy (cART).

cART is a treatment that uses a combination of three or more drugs to treat HIV infection.

While many cases of TB can be controlled with months of antibiotics, the infection can return in people who are immunocompromised as a result of HIV. A resurging TB infection — responsible for more than 1.3 million deaths worldwide — can often be deadly to these individuals.

“This is an important hurdle that this host-directed therapy had to clear in order to help patients battling both HIV and TB,” said Professor Smriti Mehra, from Texas Biomedical Research Institute (Texas Biomed)

In the study, published in the peer-reviewed journal JCI Insight, the scientist and her team focussed on the protein, called IDO (short for Indoleamine-2,3-dioxygenase) — a therapy currently used in cancer.

The host-directed therapy, already approved by the US FDA, blocks or inhibits an immune system protein naturally found in the body.

The team showed that IDO normally suppresses the immune system, preventing it from causing excessive inflammation and organ damage.

Blocking IDO for short intervals led to more successful cancer treatments.

Mehra’s team previously showed that the same approach improves control of TB in conjunction with antibiotics.

They experimented with the therapy in the current study in nonhuman primates with both TB and simian immunodeficiency virus — the nonhuman primate version of HIV.

The results showed the IDO inhibitor does not interfere with cART and is safe for patients with HIV.

Animals given cART and the IDO inhibitor showed no “increase in viral load” compared to those with only cART.

The scientist also called for longer-term studies to confirm there are no unintended side effects.

–IANS

rvt/

Go to Source

Disclaimer

The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.

Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.

Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.

For any legal details or query please visit original source link given with news or click on Go to Source.

Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.

If you are not willing to accept this disclaimer then we recommend reading news post in its original language.

RELATED ARTICLES
- Advertisment -

Most Popular